Ephemeral artery trial#

The stent fracture rate was only 3% at 1 year. At 12 months, the primary patency rate was significantly higher for patients randomized to primary stent placement based on both intention-to-treat analysis (81% vs 36%) and as-treated analysis (80% vs 61%). 5 Patients were randomized 2:1 to placement of a LifeStent (Bard Peripheral Vascular) versus balloon angioplasty.

Ephemeral artery trial#

The RESILIENT trial was the second major randomized trial to show superiority of primary stent placement over balloon angioplasty for the treatment of moderate-length SFA lesions. 3 At the same time, concerns regarding a high prevalence of stent fracture in the SFA using early generation self-expanding stents limited the broad application of stents to the femoropopliteal segment. However, other randomized studies conducted with the Luminexx stent (Bard Peripheral Vascular) failed to show a benefit of stent placement for shorter-length (mean, 40 mm) SFA lesions. At 1 year, primary patency was significantly higher for patients treated with a stent (63% vs 37%). 2 In that study, patients were randomized 1:1 to a Dynalink* or Absolute* stent (Abbott Vascular) versus balloon angioplasty. The Vienna Absolute study was the first randomized study to show superiority of primary stenting over balloon angioplasty for the treatment of moderate-length SFA lesions. SUPERIORITY OF SFA STENTS OVER BALLOON ANGIOPLASTY 1 This article reviews the historical development of SFA stent technologies, with an emphasis on recent advances and data supporting the use of stents in the SFA and popliteal arteries. Although many endovascular treatment options exist, nitinol stents remain a mainstay of SFA therapy. It is important to address any questions, concerns, allergies or sensitivities to medications with your physician prior to surgery.During the past decade, multiple technologies have been developed for treatment of superficial femoral artery (SFA) atherosclerotic disease, including balloon angioplasty, bare nitinol self-expanding stents, drug-eluting nitinol stents, and drug-coated balloons. Blockage in the surgical graft (occlusion).Irregular heartbeat ( heart arrhythmia).Some possible complications may include, but are not limited to: Your doctor will explain the risks, as well as the quality of life improvements associated with femoral popliteal bypass, so that you can make the decision that is best for you. There are risks involved with any surgical procedure. During popliteal bypass: Understanding the procedureįemoral popliteal bypass: Risks and rewards.Before popliteal bypass: Preparing for the procedure.Learn more about popliteal bypass surgery and what to expect: The best way to determine if femoral popliteal bypass is right for you is to consult with your doctor. Danger of loss of limb due to decreased blood flowįemoral popliteal bypass: What to expect?.

Intermittent Claudication or pain while at rest.

Non-healing wounds, infection or gangrene.

Disability- interference with quality of life/ ability to work.

Medical management has not improved symptoms.

There are many reasons why your doctor may recommend femoral popliteal surgery. It is important to have open communication with your doctor to understand your condition and the best ways to manage it. The decision to undergo surgery can be frightening. Reasons to perform femoral popliteal surgery

Peripheral vascular disease/peripheral arterial disease.

Femoral popliteal bypass surgery: Conditions treatedįemoral popliteal bypass surgery is used to treat conditions that affect circulation. It is performed to bypass the blocked portion of main artery in the leg using a piece of another blood vessel. Femoral popliteal (also called femoropopliteal or Fem-Pop) bypass surgery is a procedure used to treat femoral artery disease.